| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-01-12 | ralinepag | Pulmonary Arterial Hypertension |
2 | Arena Pharmaceuticals (USA - CA) | Rare diseases - Cardiovascular diseases - Respiratory diseases |
| 2015-01-12 | BMN 190 (cerliponase alfa) | late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), a form of Batten disease |
1-2 | BioMarin Pharmaceutical (USA - CA) | Rare diseases - Neurodegenerative diseases - Genetic diseases |
| 2015-01-11 | FP-1039/GSK3052230 | squamous non small cell lung cancer (sqNSCLC), mesothelioma | 1b | GSK (UK) Five Prime Therapeutics (USA - CA) | Cancer - Oncology |
| 2015-01-09 | alirocumab (SAR236553/REGN727) | hypercholesterolemia | 3 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Cardiovascular diseases - Metabolic diseases |
| 2015-01-08 | glycopyrronium bromide/NVA237 | chronic obstructive pulmonary disease (COPD) |
3 | Novartis (Switzerland) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2015-01-08 | 99mTc-rhAnnexin V-128 | rheumatoid arthritis, ankylosing spondylitis |
1-2a | Advanced Accelerator Applications (France) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Diagnostic |
| 2015-01-08 | NiCord® | blood cancers |
1-2 | Gamida Cell (Israel) | Cancer - Oncology |
| 2015-01-08 | ToleroMune® cat allergy vaccine | cat allergy |
3 | Circassia (UK) | Allergic diseases - Immunological diseases |
| 2015-01-07 | eculizumab | prevention of antibody mediated rejection (AMR) in living-donor kidney transplant recipients requiring desensitization |
2 | Alexion Pharmaceuticals (USA - CT) | Transplantation |
| 2015-01-06 | DCVAC/LuCa | stage IV non-small cell lung cancer | 1-2 | Sotio (Czech Republic) | Cancer - Oncology |
| 2015-01-06 | GFT505 | Genfit (France) | Metabolic diseases - Liver diseases | ||
| 2015-01-04 | solithromycin oral capsules | community acquired bacterial pneumonia (CABP) | 3 | Cempra (USA - NC) | Infectious diseases |
| 2015-01-01 | SAR342434 (Humalog® biosimilar - insulin lispro) | type 1 diabetes | 3 | Sanofi (France) | Metabolic diseases |
| 2015-01-01 | SAR342434 (Humalog® biosimilar - insulin lispro) | type 2 diabetes | 3 | Sanofi (France) | Metabolic diseases |
| 2015-01-00 | RG7345/RO6926496 | Alzheimer\'s disease | 1 | Roche (Switzerland) | Neurodegenerative diseases |
| 2014-12-23 | BI 409306 | Alzheimer's disease | 2 | Boehringer Ingelheim (Germany) | Neurodegenerative diseases |
| 2014-12-23 | SYN120 | Parkinson’s disease |
2a | Biotie Therapies (Finland) | Neurodegenerative diseases |
| 2014-12-22 | CF102 (Cl-IB-MECA - 2-chloro-N6-(3-iodobenzyl)-adenosine-5’- N-methyl-uronamide) | hepatocellular carcinoma |
2 | Can-Fite BioPharma (Israel) | Cancer - Oncology - Rare diseases |
| 2014-12-22 | VB-111 (ofranergene obadenovec) | thyroid cancer | 2a | VBL Therapeutics (Israel) | Cancer - Oncology |
| 2014-12-19 | gantenerumab | Alzheimer's disease | 3 | Roche (Switzerland) | Neurodegenerative diseases |
